130 related articles for article (PubMed ID: 8341019)
1. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
[TBL] [Abstract][Full Text] [Related]
2. [Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect].
Onbe T; Makino H; Haramoto T; Wada J; Ogura T; Kumagai I; Murakami K; Fukushima M; Ota Z
Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):753-9. PubMed ID: 1770635
[TBL] [Abstract][Full Text] [Related]
3. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.
Ikehara S; Shimamura K; Aoyama T; Fujii S; Hamashima Y
Immunology; 1985 Aug; 55(4):595-600. PubMed ID: 4018844
[TBL] [Abstract][Full Text] [Related]
4. The effect of 6-amidino-2-naphtyl-4-guanidinobenzoate dimethane sulfonate (FUT-175) on experimental glomerulonephritis in mice.
Nagai H; Yamada H; Matsuura N; Inagaki N; Shimazawa T; Koda A
Jpn J Pharmacol; 1984 May; 35(1):55-60. PubMed ID: 6471619
[TBL] [Abstract][Full Text] [Related]
5. [Consumption hypocomplementemia: comparative value of haemolytic and protein estimations of the components of the classical pathway (author's transl)].
Roncato M; Vial MC; Maillet F; Peltier A
Nouv Presse Med; 1979 May; 8(20):1657-60. PubMed ID: 112575
[TBL] [Abstract][Full Text] [Related]
6. New synthetic inhibitor to the alternative complement pathway.
Ikari N; Sakai Y; Hitomi Y; Fujii S
Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
[TBL] [Abstract][Full Text] [Related]
7. [Immunopharmacological actions of 6-amidino-2-naphthyl-4-guanidinobenzoate (FUT-175). 1. Effect of FUT-175 on immune response and host defense in mice].
Yanagihara Y; Shida T
Nihon Yakurigaku Zasshi; 1983 Jun; 81(6):565-72. PubMed ID: 6618346
[TBL] [Abstract][Full Text] [Related]
8. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.
Schwertz H; Carter JM; Russ M; Schubert S; Schlitt A; Buerke U; Schmidt M; Hillen H; Werdan K; Buerke M
J Cardiovasc Pharmacol; 2008 Aug; 52(2):151-60. PubMed ID: 18670364
[TBL] [Abstract][Full Text] [Related]
9. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
10. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
Mirapeix E; Yagüe J; Vives J; Revert L
Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
[TBL] [Abstract][Full Text] [Related]
11. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
Geiger H; Good RA; Day NK
Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
[TBL] [Abstract][Full Text] [Related]
12. Effects of complement suppression on xenograft survival in hyperacute rejection.
Mukai S; Orihashi K; Sueda T; Kajihara H; Matsuura Y
Hiroshima J Med Sci; 1999 Mar; 48(1):17-24. PubMed ID: 10213959
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo.
Oda M; Ino Y; Nakamura K; Kuramoto S; Shimamura K; Iwaki M; Fujii S
Jpn J Pharmacol; 1990 Jan; 52(1):23-34. PubMed ID: 1689782
[TBL] [Abstract][Full Text] [Related]
15. The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis.
Fujita T; Ohi H; Endo M; Ohsawa I; Kanmatsuse K
Clin Immunol; 1999 Jul; 92(1):97-102. PubMed ID: 10413657
[TBL] [Abstract][Full Text] [Related]
16. [Accessory use of protease-inhibiting agents for disease remission in a patient with autoimmune hemolytic anemia associated with B-CLL].
Ijichi S; Sano Y; Une F; Maruyama I; Osame M
Rinsho Ketsueki; 1990 Feb; 31(2):219-23. PubMed ID: 2329684
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Aoyama T; Ino Y; Ozeki M; Oda M; Sato T; Koshiyama Y; Suzuki S; Fujita M
Jpn J Pharmacol; 1984 Jul; 35(3):203-27. PubMed ID: 6482087
[TBL] [Abstract][Full Text] [Related]
18. The complement abnormalities of lipodystrophy.
Sissons JG; West RJ; Fallows J; Williams DG; Boucher BJ; Amos N; Peters DK
N Engl J Med; 1976 Feb; 294(9):461-5. PubMed ID: 1246331
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitor nafamostat mesilate attenuates complement activation and improves function of xenografts in a discordant lung perfusion model.
Tagawa T
Xenotransplantation; 2011; 18(6):315-9. PubMed ID: 22168138
[TBL] [Abstract][Full Text] [Related]
20. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175.
Miyamoto Y; Hirose H; Matsuda H; Nakano S; Ohtani M; Kaneko M; Nishigaki K; Nomura F; Kitamura H; Kawashima Y
Trans Am Soc Artif Intern Organs; 1985; 31():508-11. PubMed ID: 3837498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
